<DOC>
	<DOCNO>NCT00456807</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Indeed , certain oncogenic type HPV infect cervix ( part uterus womb ) . This infection may go away , go away ( call persistent infection ) , lead woman long period time cancer cervix . This study supplement ongoing study evaluate safety , efficacy immunogenicity vaccine woman age 26 year . This study therefore assess additional immunogenicity parameter vaccine woman select investigative site . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Complementary Testing Evaluate Immunogenicity Human Papillomavirus ( HPV ) Vaccine ( 580299 ) Healthy Female Subjects Aged &gt; /= 26 Years</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female enrol study 104820 receive three dos study vaccine/control . Subjects investigator believe comply requirement protocol enrol study . Written inform consent obtain subject prior enrolment ancillary study . Pregnancy . Administration HPV vaccine foreseen study protocol . Use investigational nonregistered product ( drug vaccine ) study vaccine since study start . Chronic administration immunosuppressant immunemodifying drug since study start . Administration immunoglobulins and/or blood product within 90 day precede blood sampling .</criteria>
	<gender>Female</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Human Papillomavirus</keyword>
</DOC>